carmustine has been researched along with Bare Lymphocyte Syndrome in 2 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Zielske, SP | 1 |
Reese, JS | 1 |
Lingas, KT | 1 |
Donze, JR | 1 |
Gerson, SL | 1 |
Cai, S | 1 |
Hartwell, JR | 1 |
Cooper, RJ | 1 |
Juliar, BE | 1 |
Kreklau, E | 1 |
Abonour, R | 1 |
Goebel, WS | 1 |
Pollok, KE | 1 |
2 other studies available for carmustine and Bare Lymphocyte Syndrome
Article | Year |
---|---|
In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning.
Topics: Animals; Antigens, CD34; Antineoplastic Agents; Carmustine; Gene Transfer Techniques; Genetic Vector | 2003 |
In vivo effects of myeloablative alkylator therapy on survival and differentiation of MGMTP140K-transduced human G-CSF-mobilized peripheral blood cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood Cells; Carmustine; Cell Differentiation; Cell Surv | 2006 |